Targeted stabilization of Munc18‐1 function via pharmacological chaperones
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Heterozygous de novo mutations in the neuronal protein Munc18-1 cause syndromic neurological symptoms, including severe epilepsy, intellectual disability, developmental delay, ataxia, and tremor. No disease-modifying therapy exists to treat these disorders, and while chemical chaperones have been shown to alleviate neuronal dysfunction caused by missense mutations in Munc18-1, their required high concentrations and potential toxicity necessitate a Munc18-1-targeted therapy. Munc18-1 is essential for neurotransmitter release, and mutations in Munc18-1 have been shown to cause neuronal dysfunction via aggregation and co-aggregation of the wild-type protein, reducing functional Munc18-1 levels well below hemizygous levels. Here, we identify two pharmacological chaperones via structure-based drug design, that bind to wild-type and mutant Munc18-1, and revert Munc18-1 aggregation and neuronal dysfunction in vitro and in vivo, providing the first targeted treatment strategy for these severe pediatric encephalopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“Additionally, levetiracetam, a known anti-epileptic that is thought to bind to synaptic vesicle protein SV2a (Lynch et al , 2004), was included in our screen, as it provides a synaptic therapy that does not go through Munc18-1 and has led to seizure freedom in several patients with Munc18-1 mutations (Dilena et al , 2…”
De novo mutations in epileptic encephalopathies
Epi4K Consortium, & Epilepsy Phenome/Genome Project (2013) · Nature · doi:10.1038/nature12439 · Cited by 1,514
The mechanisms and functions of spontaneous neurotransmitter release
Kavalali, E. T. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3875 · Cited by 486 · cited 1×
“This discrepancy may be due to the fact that a different synaptic machinery is involved in evoked versus spontaneous release (Kavalali, 2015).”
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 2×
“Several studies have successfully identified small molecule mimetics for BDNF from in silico studies that are able to either specifically activate or antagonize TrkB, the BDNF receptor, and are also active in vivo (Massa et al , 2010; Cazorla et al , 2011) .”
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Doc2b Is a High-Affinity Ca 2+ Sensor for Spontaneous Neurotransmitter Release
Groffen, A. J., Martens, S., Arazola, R. D., Cornelisse, L. N., Lozovaya, N., de Jong, A. P. H., Goriounova, N. A., Habets, R. L. P., Takai, Y., Borst, J. G., et al. (2010) · Science · doi:10.1126/science.1183765 · Cited by 313
In silico design of novel probes for the atypical opioid receptor MRGPRX2
Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2334 · Cited by 293 · cited 2×
“Despite these caveats, structure-based drug design has been successfully used in multiple fields (Massa et al , 2006; Massa et al , 2010; Cazorla et al , 2011; Mecozzi et al , 2014; Gao et al , 2015; Lansu et al , 2017; Rivat et al , 2018; Li et al , 2020).”
Cited by
Assessing the landscape of STXBP1 -related disorders in 534 individuals
Xian, J., Parthasarathy, S., Ruggiero, S. M., Balagura, G., Fitch, E., Helbig, K., Gan, J., Ganesan, S., Kaufman, M. C., Ellis, C. A., et al. (2022) · Brain · doi:10.1093/brain/awab327 · Cited by 130
(2024) · doi:10.7554/elife.88619.3 · Cited by 17
Kádková, A., Murach, J., Østergaard, M., Malsam, A., Malsam, J., Lolicato, F., Nickel, W., Söllner, T. H., & Sørensen, J. B. (2024) · doi:10.7554/elife.88619.2
Metadata
- Authors
- Abramov, D., Guiberson, N. G. L., Daab, A., Na, Y., Petsko, G. A., Sharma, M., & Burré, J.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-17
- Volume
- 13
- Issue
- 1
- Pages
- e12354-e12354
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3111586828
- Cited by
- 24
- References
- 7
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted stabilization of Munc18‐1 function via pharmacological chaperones. https://app.cochat.ai/papers/10.15252/emmm.202012354
- The paper
- Abramov, D., Guiberson, N. G. L., Daab, A., Na, Y., Petsko, G. A., Sharma, M., & Burré, J. (2021). Targeted stabilization of Munc18‐1 function via pharmacological chaperones. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.